Group 1 - Company shares of 基石药业-B (02616) increased by over 5%, reaching a price of 6.07 HKD with a trading volume of 22.7042 million HKD [1] - The company announced that its RET inhibitor, 普吉华 (普拉替尼胶囊, 100mg), has been successfully included in the latest National Medical Insurance Catalog, effective from January 1, 2026 [1] - To date, 基石药业 has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national insurance catalog [1] Group 2 - Tianfeng Securities published a report in August, predicting that the inclusion of 普拉替尼 in the insurance catalog is expected to accelerate its market penetration [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - The innovative internal ADC technology platform of the company features optimized proprietary linkers to improve the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for future development [1]
基石药业-B涨超5% 普拉替尼获纳入国家医保目录 公司2.0管线矩阵持续扩大